Gangtok Chronicle

Hypertrophic Cardiomyopathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Hypertrophic Cardiomyopathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 18
17:30 2021
Hypertrophic Cardiomyopathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Hypertrophic Cardiomyopathy – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Hypertrophic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Hypertrophic Cardiomyopathy Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Hypertrophic Cardiomyopathy pipeline landscapes. 

The report comprises Hypertrophic Cardiomyopathy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hypertrophic Cardiomyopathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hypertrophic Cardiomyopathy pipeline products.    

 

Hypertrophic Cardiomyopathy Overview

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). HCM occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. The ventricle size often remains normal, but the thickening may block blood flow out of the ventricle. If this happens, the condition is called Obstructive hypertrophic cardiomyopathy (HOCN). Sometimes the septum, the wall that divides the left and right sides of the heart, thickens and bulges into the left ventricle. This can block blood flow out of the left ventricle. Then the ventricle must work hard to pump blood. Symptoms can include chest pain, dizziness, shortness of breath, or fainting.

Some of the key takeaways from the Hypertrophic Cardiomyopathy Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Bristol Myers Squibb, Cytokinetics, Novartis, Bristol Myers Squibb, Celltrion, Palatin Technologies, etc., are developing therapies for the treatment of Hypertrophic Cardiomyopathy.

  • Emerging therapies such as Mavacamten, CK-274, LCZ-696, MYK-224, CT-G20, PL-5028, are expected to have a significant impact on the  Hypertrophic Cardiomyopathy market in the coming years.

Get an overview of pipeline landscape @ Hypertrophic Cardiomyopathy Clinical Trials Analysis 

Hypertrophic Cardiomyopathy Pipeline Therapies along with Key Players:

  • Mavacamten: Bristol Myers Squibb

  • CK-274: Cytokinetics

  • LCZ-696: Novartis

  • MYK-224: Bristol Myers Squibb

  • CT-G20: Celltrion

  • PL-5028: Palatin Technologies 

Scope of Hypertrophic Cardiomyopathy Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Bristol Myers Squibb, Cytokinetics, Novartis, Bristol Myers Squibb, Celltrion, Palatin Technologies, and others.

  • Pipeline Therapies: CK-274, LCZ-696, MYK-224, CT-G20, PL-5028, and others.

Table of Contents

1

Hypertrophic Cardiomyopathy Report Introduction

2

Hypertrophic Cardiomyopathy Executive Summary

3

Hypertrophic Cardiomyopathy Overview

4

Hypertrophic Cardiomyopathy- Analytical Perspective In-depth Commercial Assessment

5

Hypertrophic Cardiomyopathy Pipeline Therapeutics

6

Hypertrophic Cardiomyopathy Late Stage Products (Phase II/III)

7

Hypertrophic Cardiomyopathy Mid Stage Products (Phase II)

8

Hypertrophic Cardiomyopathy Early Stage Products (Phase I)

9

Hypertrophic Cardiomyopathy Preclinical Stage Products

10

Hypertrophic Cardiomyopathy Therapeutics Assessment

11

Hypertrophic Cardiomyopathy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Hypertrophic Cardiomyopathy Key Companies

14

Hypertrophic Cardiomyopathy Key Products

15

Hypertrophic Cardiomyopathy Unmet Needs

16 

Hypertrophic Cardiomyopathy Market Drivers and Barriers

17

Hypertrophic Cardiomyopathy Future Perspectives and Conclusion

18

Hypertrophic Cardiomyopathy Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Hypertrophic Cardiomyopathy Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/